China

Former U.S. President Donald Trump has expressed support for a proposed sanctions bill aimed at countries continuing to import Russian crude, placing India and China under renewed geopolitical and economic scrutiny. The move signals a potential hardening of Washington’s stance on global energy trade linked to the Russia-Ukraine conflict. If enacted, the legislation could disrupt established oil procurement strategies, increase market volatility, and complicate diplomatic equations for major emerging economies.

Chinese technology firm GravityXR has announced the development of a cutting-edge spatial computing chip, marking a significant stride in immersive computing and augmented reality (AR)/virtual reality (VR) applications. The chip is designed to deliver enhanced real-time 3D rendering, reduced latency, and improved energy efficiency, positioning GravityXR at the forefront of China’s burgeoning spatial computing market.

India’s seafood industry, a major pillar of the country’s agri-export basket, is facing renewed headwinds as the United States considers higher import tariffs on certain marine products. The US, which accounts for nearly one-third of India’s seafood exports, remains a vital market for shrimp and frozen fish. However, with protectionist trade measures tightening, exporters are exploring opportunities in Japan, China, the European Union, and West Asia to diversify their customer base.

Tata Motors is positioning itself to achieve price parity with Chinese electric vehicle (EV) manufacturers, a move that could redefine India’s role in the global EV market. By focusing on cost-efficient battery technologies, local supply chain development, and economies of scale, Tata aims to bring its EV offerings closer to the affordability of Chinese models without compromising on quality and safety. The strategy reflects the company’s ambition to expand its footprint both in domestic and overseas markets.

Aurobindo Pharma’s manufacturing facility in China is on the cusp of achieving break-even, signaling a pivotal turnaround for the company’s international operations. The plant, which focuses on active pharmaceutical ingredients (APIs) and finished dosage formulations, has benefited from optimized production processes, stringent cost controls, and growing demand in both domestic and export markets. Analysts note that reaching break-even will enhance Aurobindo’s global competitiveness and support its expansion strategy in Asia.

Aurobindo Pharma, one of India’s leading pharmaceutical manufacturers, announced that its facility in China is expected to achieve break-even in the near term, signaling progress in the company’s global expansion strategy. The plant, which plays a critical role in the supply of key raw materials and intermediates, has been a significant investment aimed at reducing dependency on third-party suppliers.